Elise E DeVito1, Brian D Kiluk2, Charla Nich2, Maria Mouratidis3, Kathleen M Carroll2. 1. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. Electronic address: elise.devito@yale.edu. 2. Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA. 3. Department of Psychology, Notre Dame of Maryland University, Baltimore, MD, USA.
Abstract
BACKGROUND: Poor performance on Drug Stroop tasks, which could indicate attentional bias to drug-related cues, craving, poor cognitive control (including poor response inhibition), has been associated with substance use severity, treatment retention and substance use treatment outcomes. Cognitive Behavioral Therapy (CBT) focuses on training in appraisal and coping strategies, including strategies to minimize the negative impact of triggers and coping with drug-cue-induced craving. One mechanism of action of CBT may be the strengthening of cognitive control processes and reduction of attentional bias to drug-related stimuli. METHODS:Methadone-maintained individuals with cocaine-use disorders, participating in a randomized controlled trial of treatment as usual (TAU) versus TAU plus access to computer-based CBT (CBT4CBT), completed a computerized Drug Stroop task at pre- and post-treatment. Analyses determined whether attentional bias toward drug-related stimuli changed differentially by treatment group or cocaine use outcomes across the treatment period and whether engagement in components of CBT4CBT or TAU treatment related to changes in attentional bias toward drug-related stimuli at post- versus pre-treatment. RESULTS: Participants achieving a longer duration of cocaine abstinence during treatment (3+ weeks) showed greater reductions in Drug Stroop Effect than those with shorter maximum continuous abstinence. Reductions in Drug Stroop Effect across treatment were associated with greater engagement with CBT4CBT-specific treatment components, but not TAU-specific treatment components. CONCLUSIONS: Reduction in attentional bias to drug-related cues and craving and/or improved executive cognitive control and response inhibition may contribute to the mechanism of action of CBT4CBT.
RCT Entities:
BACKGROUND: Poor performance on Drug Stroop tasks, which could indicate attentional bias to drug-related cues, craving, poor cognitive control (including poor response inhibition), has been associated with substance use severity, treatment retention and substance use treatment outcomes. Cognitive Behavioral Therapy (CBT) focuses on training in appraisal and coping strategies, including strategies to minimize the negative impact of triggers and coping with drug-cue-induced craving. One mechanism of action of CBT may be the strengthening of cognitive control processes and reduction of attentional bias to drug-related stimuli. METHODS:Methadone-maintained individuals with cocaine-use disorders, participating in a randomized controlled trial of treatment as usual (TAU) versus TAU plus access to computer-based CBT (CBT4CBT), completed a computerized Drug Stroop task at pre- and post-treatment. Analyses determined whether attentional bias toward drug-related stimuli changed differentially by treatment group or cocaine use outcomes across the treatment period and whether engagement in components of CBT4CBT or TAU treatment related to changes in attentional bias toward drug-related stimuli at post- versus pre-treatment. RESULTS:Participants achieving a longer duration of cocaine abstinence during treatment (3+ weeks) showed greater reductions in Drug Stroop Effect than those with shorter maximum continuous abstinence. Reductions in Drug Stroop Effect across treatment were associated with greater engagement with CBT4CBT-specific treatment components, but not TAU-specific treatment components. CONCLUSIONS: Reduction in attentional bias to drug-related cues and craving and/or improved executive cognitive control and response inhibition may contribute to the mechanism of action of CBT4CBT.
Authors: Kathleen M Carroll; Samuel A Ball; Steve Martino; Charla Nich; Theresa A Babuscio; Kathryn F Nuro; Melissa A Gordon; Galina A Portnoy; Bruce J Rounsaville Journal: Am J Psychiatry Date: 2008-05-01 Impact factor: 18.112
Authors: Kathleen M Carroll; Samuel A Ball; Steve Martino; Charla Nich; Theresa A Babuscio; Bruce J Rounsaville Journal: Drug Alcohol Depend Date: 2008-11-28 Impact factor: 4.492
Authors: Marc L Copersino; Mark R Serper; Nehal Vadhan; Brett R Goldberg; Danielle Richarme; James C-Y Chou; Maxine Stitzer; Robert Cancro Journal: Psychiatry Res Date: 2004-10-30 Impact factor: 3.222
Authors: Karen D Ersche; Edward T Bullmore; Kevin J Craig; Shaila S Shabbir; Sanja Abbott; Ulrich Müller; Cinly Ooi; John Suckling; Anna Barnes; Barbara J Sahakian; Emilio V Merlo-Pich; Trevor W Robbins Journal: Arch Gen Psychiatry Date: 2010-06
Authors: Craig R Rush; Justin C Strickland; Erika Pike; Christina R Studts; William W Stoops Journal: Drug Alcohol Depend Date: 2019-12-16 Impact factor: 4.492
Authors: Andy C Dean; Erika L Nurmi; Scott J Moeller; Nader Amir; Michelle Rozenman; Dara G Ghahremani; Maritza Johnson; Robert Berberyan; Gerhard Hellemann; Ziwei Zhang; Edythe D London Journal: Psychopharmacology (Berl) Date: 2018-11-10 Impact factor: 4.530
Authors: Melvyn W B Zhang; Jiangbo Ying; Tracey Wing; Guo Song; Daniel S S Fung; Helen E Smith Journal: Front Psychiatry Date: 2018-08-15 Impact factor: 4.157
Authors: Melvyn Zhang; Jiangbo Ying; Tracey Wing; Guo Song; Daniel S S Fung; Helen Smith Journal: Int J Environ Res Public Health Date: 2018-06-01 Impact factor: 3.390
Authors: Farhud Shams; James S H Wong; Mohammadali Nikoo; Ava Outadi; Ehsan Moazen-Zadeh; Mostafa M Kamel; Michael Jae Song; Kerry L Jang; Reinhard Michael Krausz Journal: J Med Internet Res Date: 2021-01-21 Impact factor: 5.428